Vistagen presents new research on the impact of social anxiety disorder at the anxiety and depression association 2025 conference

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (sad) at the 2025 anxiety and depression association of america (adaa) conference in las vegas, nevada. the company's poster presentations examined the age of onset of sad in participants in.
VTGN Ratings Summary
VTGN Quant Ranking